Life Sciences

Ed Giniat

‹

›

Ed Giniat

Partner, National Sector Leader, Healthcare , KPMG (US)

+1 312-665-2073

Email Me

Embracing transparency

Instead of viewing calls for transparency as a burden, pharmaceutical companies can take steps to turn pricing reform to their advantage.

Read more
Prescription drug rebates

Proposed safe harbor changes open for comment

Read more
Part D Payment Modernization Model

Consider applying for the voluntary initiative

Read more
Driving value from genomics in Life Sciences

Rising to the data challenge

Read more
R&D 2030

Reinvent innovation and become an R&D front-runner by 2030

Read more
Opportunities in an Evolving Market

2019 Health Care & Life Sciences Investment Outlook

Read more
Digital transformation in regulatory affairs

Unlocking value for life sciences organizations

Read more
Pharmaceuticals industry exec summary - Harvey Nash/KPMG CIO survey 2018

This CIO Survey is the largest IT leadership study in the world, and summarizes what we learned about the transformational CIO.

Read more
The race to EU MDR compliance

KPMG/RAPS survey illustrates the ground medical device companies still have to cover

Read more
Insider threat in life sciences

2018 Program benchmark report

Read more
Digital health and disruption in diabetes

Identifying opportunities for life sciences manufacturers.

Read more
Future of finance: Finance disrupted

Innovation in the life sciences finance function

Read more
The disruption challenge

As new entrants and cross-sector models abound, which direction should healthcare organizations turn?

Read more
Demystifying blockchain for life sciences

Blockchain could be a key to interoperability and privacy

Read more
Pricing for survival

As demand for pharmaceutical cost containment intensifies, novel drug-pricing approaches are critical

Read more
Revenue for the life sciences industry

New standard. New challenges.

Read more
Medical devices 2030

Making a power play to avoid the commodity trap

Read more
2018 Health care & life sciences investment outlook

Healthcare and life sciences will face continued disruption in 2018 as new technologies, economic pressures and consumer/patient demands change the industry.

Read more
Top trends and risks for 2018

Navigating a transforming life sciences landscape

Read more
Personalized care requires personal data

GDPR in Life Sciences Reference Card

Read more
The future of oncology:

A focused approach to winning in 2030

Read more
Is teaming the key to medical device cyber security?

Work together to strike a balance between strong cyber-security measures and the ability to treat patients

Read more
Life sciences innovation and cyber security: Inseparable

Breakthrough drugs and devices present greater opportunities…and risks

Read more
Medical device cybersecurity and privacy:

Medical device "Frameworks and standards

Read more
2017 Serialization and traceability trends

A closer look

Read more

Related content

KPMG Healthcare & Life Sciences Institute

Register to receive timely insights